2
Participants
Start Date
July 31, 2008
Primary Completion Date
November 30, 2011
Study Completion Date
November 30, 2011
gemcitabine and cisplatin plus sorafenib
Gemcitabine 1000 mg/m 2 will be administered on days 1 and 8 and cisplatin 35 mg/m 2 will be administered on days 1 and 8. A total of six cycles of therapy will be administered at 21day intervals. Sorafenib 400 mg PO twice daily will be initiated on day 1 of cycle 1 and continued, as tolerated, until the time of disease progression or a maximum of 12 months. The total chemotherapy dose for gemcitabine and cisplatin (GC) may be modified for patients with severe obesity (e.g. body surface area (BSA) \> 2.1), after consultation with the Principal Investigator.
Memorial Sloan Kettering Cancer Center, New York
Collaborators (1)
Bayer
INDUSTRY
Memorial Sloan Kettering Cancer Center
OTHER